Most Popular Stories
- IOM: Chronic conditions a public health 'crisis'
- Healthcare jobs will grow the fastest of all industries
- New Jersey a hotbed for hospital consolidation
- Hospitals ready for value-based purchasing with higher patient satisfaction
- U of California students launch telehealth pilot for diabetes
- MGMA protests 5010-related payment delays, demands government action
Featured Jobs
-
ICD-10 Revenue Cycle, Manager
Meditology Services - Atlanta, GA -
Epic Ambulatory Beacon Consultant
Meditology Services - NC
Events
- From IHI: The Patient Experience Seminar
March 27-28 — Boston, MA - ICD-10 Reality Check - Breakfast Panel at HiMSS 2012!
February 22, 2012 - Wharton Health Care Business Conference
Feb 16-17 — Philadelphia, PA - IHI's Transforming the Primary Care Practice
May 1-3, 2012 — San Diego, CA
Paid Research Reports
- Electronic health records: getting it right first time
- Cloud Computing Adoption In The APAC Life Sciences Industry
- Stakeholder Opinions: Ophthalmology - Leading brands under threat
- Genomics, Proteomics and Metabolomics in Diagnostics: Market landscape, innovative technologies and future outlook
- Healthcare Regulatory Update: The United Arab Emirates
- Point of Care Testing: Evaluating the return to evidence based medicine, novel technologies and the competitive landscape
Free Newsletter
FierceHealthcare is the leading source of healthcare management news for healthcare industry executives. Join 50,000+ healthcare industry insiders who get FierceHealthcare via daily email. Sign up today!
Popular Topics
Off-label use of narcotic raises questions
Narcotic painkiller Actiq, which is FDA-approved only for use in treating cancer pain, is widely prescribed for conditions such as migraines and backache as well. With growing numbers of patients becoming addicted to Actiq, which contains fentanyl, government regulators and physicians are investigating whether drug-maker Cephalon has been illegally marketing off-label use to physicians. Despite its approved target audience, oncologists accounted for only 1 percent of the 187,076 Actiq prescriptions filled at retail pharmacies in the U.S. during the first six months of 2006, The Wall Street Journal reported. Now FDA regulators are investigating whether Cephalon marketers have targeted non-oncologists. The drug maker does not dispute that it sends its drug reps to specialists of many stripes, but disputes charges that it is violating FDA requirements.
Get the whole Actiq story:
- read this piece in the Wall Street Journal (sub. req.)
Related Article:
The FDA approves Cephalon's Fentora for cancer pain. Report
Related Stories
- FL sues Merck over Vioxx marketing
- SPOTLIGHT: Fentanyl deaths top 1,000 over two years
- Case study: Kaiser physicians go on sales calls
- Judge overturns GA's medical malpractice damages limit
- San Francisco agrees to $5M medical malpractice settlement
- ALSO NOTED: EMRs may not save much money; Duke plans big expansion; and much more...
- Hot topics at the MGMA
- Study: Few painkillers, pain specialists in poor countries
- Wash. state program increases pain med use
- Primary care MDs ask patients for extra dollars
Home
| Subscribe | Advertise | Mobile Edition | RSS |
Privacy
| Site Map
| Editors | List in Marketplace | Supplier in MarketplaceTHE FIERCEMARKETS NETWORKFierceEnergy | FierceSmartGrid | FierceFinance | FierceFinanceIT | FierceComplianceIT | FierceHealthcare | FierceHealthFinance | FierceHealthIT | Hospital Impact | FierceMobileHealthcare | FierceHealthPayer | FiercePracticeManagement | FierceEMR | FierceCIO | FierceCIO:TechWatch | FierceContentManagement | FierceMobileIT | FierceGovernmentIT | FierceGovernment | FierceHomelandSecurity | FierceBiotech | FierceBiotech Research | FiercePharma | FierceVaccines | FierceBiotechIT | FiercePharma Manufacturing | FierceMedicalDevices | FierceDrugDelivery | FierceIPTV | FierceOnlineVideo | FierceTelecom | FierceEnterpriseCommunications | FierceBroadbandWireless | FierceDeveloper | FierceMobileContent | FierceWireless | FierceWireless:Europe | FierceCable© 2011 FierceMarkets. All rights reserved. |
![]() |
